Respiri Ltd
ASX:RSH
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.022
0.096
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Respiri Ltd
Total Receivables
Respiri Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Respiri Ltd
ASX:RSH
|
Total Receivables
AU$253.1k
|
CAGR 3-Years
23%
|
CAGR 5-Years
9%
|
CAGR 10-Years
12%
|
|
|
ImpediMed Ltd
ASX:IPD
|
Total Receivables
AU$3.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
22%
|
|
|
C
|
Cyclopharm Ltd
ASX:CYC
|
Total Receivables
AU$8.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
19%
|
CAGR 10-Years
10%
|
|
|
Cochlear Ltd
ASX:COH
|
Total Receivables
AU$502m
|
CAGR 3-Years
11%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Total Receivables
AU$1.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
30%
|
CAGR 10-Years
9%
|
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Total Receivables
AU$2.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
123%
|
CAGR 10-Years
N/A
|
|
Respiri Ltd
Glance View
Respiri Ltd. engages in research, development, and commercialization of medical devices and the production of mobile health applications for management of asthma and related chronic respiratory diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2000-07-14. The firm's segments include Australia and Israel. The Australia segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Australia. The Israel segment is engaged in research, development and commercialization of medical devices, and the production of mobile health applications in Israel. The firm has developed a wheezo, which is an eHealth Saas platform that uses a device and app to measure, record and assist asthma monitoring. Its device and app make up a cloud-based mobile health platform that records wheeze and other clinically relevant symptoms and signs of asthma.
See Also
What is Respiri Ltd's Total Receivables?
Total Receivables
253.1k
AUD
Based on the financial report for Jun 30, 2024, Respiri Ltd's Total Receivables amounts to 253.1k AUD.
What is Respiri Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
12%
Over the last year, the Total Receivables growth was 436%. The average annual Total Receivables growth rates for Respiri Ltd have been 23% over the past three years , 9% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet
